Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories is viewed positively because management is signaling a meaningful retooling of the business, with a mid-teens EBIT margin objective versus the 11% guided midpoint for 2026 and a systematic restructuring that began in late 2025 across commercial, operating, and earlier R&D expenses. Investors also see improving fundamentals as Q2 helped de-risk the 2H ramp, end markets are stabilizing, and product pressures in process chromatography are expected to ease, supporting faster sales growth when headwinds lapse. Additional upside comes from the company’s ~33% stake in Sartorius, whose optionality should increase in mid-2028 when the controlling Trust terminates, while Bio-Rad’s core diagnostics and life sciences franchises remain well positioned across global markets.

Bio-Rad Laboratories is facing a negative outlook because its life science tools business still depends on an end-market recovery that has taken years to normalize and may not arrive, while its ddPCR franchise has been losing share to Qiagen over the past several years. The company also carries structural risk from a business mix exposed to wet-lab research, potential AI-driven shifts away from that work, and a mixed M&A record that heightens execution risk. On top of that, further multiple erosion and a steeper discount to the Sartorius stake could reflect fading investor confidence in sales and margin trajectory, while dual-class governance concentrates control with the Schwartz family and may not align with broader shareholders.